Nanotechnology-based disinfectants and sensors for SARS-CoV-2

Sepehr Talebian^{1

2

3}, Gordon G Wallace¹, Avi Schroeder⁴, Francesco Stellacci^{5

6}, João Conde^{7

8}

Affiliations

¹ Intelligent Polymer Research Institute, ARC Centre of Excellence for Electromaterials Science, AIIM Facility, University of Wollongong, Wollongong, New South Wales, Australia.
² Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, New South Wales, Australia.
³ Apiam Animal Health Pty Ltd, East Bendigo, Victoria, Australia.
⁴ Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa, Israel. avids@technion.ac.il.
⁵ Institute of Materials, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. francesco.stellacci@epfl.ch.
⁶ Interfaculty Bioengineering Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. francesco.stellacci@epfl.ch.
⁷ NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal. joao.conde@nms.unl.pt.
⁸ Centre for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal. joao.conde@nms.unl.pt.

Sepehr Talebian et al. Nat Nanotechnol. 2020 Aug.

. 2020 Aug;15(8):618-621.

doi: 10.1038/s41565-020-0751-0.

Sepehr Talebian^{1

2

3}, Gordon G Wallace¹, Avi Schroeder⁴, Francesco Stellacci^{5

6}, João Conde^{7

8}

¹ Intelligent Polymer Research Institute, ARC Centre of Excellence for Electromaterials Science, AIIM Facility, University of Wollongong, Wollongong, New South Wales, Australia.
² Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, New South Wales, Australia.
³ Apiam Animal Health Pty Ltd, East Bendigo, Victoria, Australia.
⁴ Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa, Israel. avids@technion.ac.il.
⁵ Institute of Materials, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. francesco.stellacci@epfl.ch.
⁶ Interfaculty Bioengineering Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. francesco.stellacci@epfl.ch.
⁷ NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal. joao.conde@nms.unl.pt.
⁸ Centre for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal. joao.conde@nms.unl.pt.

No abstract available

References

1. Hu, T. Y., Frieman, M. & Wolfram, J. Nat. Nanotechnol. 15, 247–249 (2020). - DOI
1. Liu, C. et al. ACS Cent. Sci. 6, 315–331 (2020). - DOI
1. Dourado, E. Accelerating Availability of Vaccine Candidates for COVID-19 Special Edition Policy Brief (Mercatus Center Research, George Mason University, 2020).
1. Itani, R., Tobaiqy, M. & Al Faraj, A. Theranostics 10, 5932–5942 (2020). - DOI
1. Peng, X. et al. Int. J. Oral. Sci. 12, 1–6 (2020). - DOI